Lilian Zhou Appointed to STAAR Surgical Board of Directors
December 04 2023 - 4:05PM
Business Wire
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of the EVO family of Implantable
Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia,
today announced the appointment of Lilian Zhou to its Board of
Directors, effective December 4, 2023.
“We welcome Lilian Zhou as a new member to our Board of
Directors. Lilian is an accomplished investment portfolio manager
who worked at highly regarded Wall Street investment institutions
before founding her own firm a decade ago,” said Aimee Weisner,
Chair of the Nominating and Governance Committee of STAAR
Surgical’s Board of Directors. "We look forward to Lilian’s
contributions as a former institutional shareholder of STAAR with
an in-depth and global perspective of healthcare, ophthalmology and
STAAR’s opportunity."
Lilian Zhou brings more than two decades of capital markets and
investment experience to STAAR. Most recently, Ms. Zhou was
Founder, Chief Investment Officer and Managing Partner of Yulan
Capital Management, a Tiger Seed, which operated out of New York
and Shanghai from 2013 through June 2023. Prior to Yulan Capital,
Ms. Zhou worked at Citadel, Kelusa Capital and Bear Stearns &
Co. Lilian began her career as an investment banking analyst at
Credit Suisse in 2004. Ms. Zhou is a Chartered Financial Analyst
(CFA) and holds a Bachelor of Arts, Economics and
Mathematics-Statistics, from Columbia University and an MBA from
The Wharton School, University of Pennsylvania.
STAAR also reported today that Gil Kliman, M.D., has decided to
leave the board, effective December 1, in order to more fully
devote his time and energies to his other commitments. Tom Frinzi,
STAAR’s Chair of the Board, stated, “STAAR has benefitted greatly
from Dr. Kliman’s extensive ophthalmology, commercial and medical
device experience and we sincerely thank Gil for his dedicated
service. He has been a steadfast supporter of STAAR, and we hope to
continue to benefit from his insights in the future.”
Other current members of STAAR’s Board of Directors include
Stephen Farrell, Tom Frinzi, Aimee Weisner, Elizabeth Yeu, M.D.,
and K. Peony Yu, M.D.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 2,500,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231204167217/en/
Investors & Media Brian Moore Vice President,
Investor Relations and Corporate Development (626) 303-7902, Ext.
3023 bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Apr 2024 to May 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From May 2023 to May 2024